Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. (a foreign private issuer) covers the month of February 2026, specifically reporting on an induced warrant exercise transaction announced on February 10, 2026, with an expected closing date of February 11, 2026.
Key Financial Metrics
- Expected Gross Proceeds: Approximately $3.4 million from the exercise of existing warrants.
- Transaction Fees: A cash fee of 7.0% of gross proceeds payable to the advisor (A.G.P./Alliance Global Partners), plus reimbursement of legal expenses up to $20,000.
- Use of Proceeds: General corporate purposes.
- Debt and Liquidity: The filing does not provide specific data on total debt, cash balances, or liquidity ratios outside of the proceeds from this specific transaction.
Material Changes and Transaction Details
The Company entered into an inducement agreement with a holder of 3,384,616 existing warrants (Series A and Series B) originally issued in August 2024 with an exercise price of $3.55 per share.
- Price Reduction: The exercise price for the existing warrants was reduced to $1.00 per share to induce immediate cash exercise.
- Share Issuance: The Company will issue 3,384,616 ordinary shares upon exercise.
- New Warrants Issued: In consideration for the price reduction, the Company issued 5,076,924 new warrants (Series A-1 and Series B-1) to the holder.
- New Warrant Terms:
- Exercise Price: $1.25 per share.
- Series A-1 Term: 5 years.
- Series B-1 Term: 18 months.
- Ownership Cap: Holder cannot exercise if it would result in ownership exceeding 4.99% of outstanding shares.
Guidance, Outlook, and Risks
- Market Restrictions: The Company agreed to a 45-day lock-up period (through March 28, 2026) on issuing new shares or filing new registration statements, with exceptions for "At-the-market" offerings starting 15 days post-closing. A six-month restriction on Variable Rate Transactions also applies.
- Liquidity Risk: There is no established trading market for the new warrants, and the Company does not expect one to develop, resulting in extremely limited liquidity for these instruments.
- Closing Contingencies: The transaction is subject to customary closing conditions; failure to satisfy these conditions may prevent the transaction from closing.
- Registration: The Company must file a resale registration statement for the new warrant shares within 50 days and seek effectiveness within 80 days (or 110 days if a full review is required).
Investor Verification Checklist
- Verify the actual closing of the transaction and the receipt of the ~$3.4 million in gross proceeds.
- Confirm the effective date of the resale registration statement (Form F-3) for the new warrant shares.
- Monitor the Company's compliance with the 45-day lock-up period and the six-month restriction on Variable Rate Transactions.
- Review the impact of the 5,076,924 new warrants on future dilution, noting the $1.25 exercise price.
- Check for any subsequent filings regarding the "At-the-market" offering exception mentioned in the lock-up terms.